14Aims: Use of sodium–glucose co-transporter 2 inhibitors (SGLT2i) in real-world heart failure (HF) is poorly characterised. In contemporary patients with HF and type 2 diabetes mellitus (T2DM) we assessed over time SGLT2i use, clinical characteristics and outcomes associated with SGLT2i use. Methods and results: Type 2 diabetes patients enrolled in the Swedish HF Registry between 2016–2018 were considered. We performed multivariable logistic regression models to assess the independent predictors of SGLT2i use and Cox regression models in a 1:3 propensity score-matched cohort and relevant subgroups to investigate the association between SGLT2i use and outcomes. Of 6805 eligible HF patients with T2DM, 376 (5.5%) received SGLT2i, whose use in...
Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) were originally developed for the treatment of ...
Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise g...
Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise g...
Aims Use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in real-world heart failure (HF) is ...
AIMS: Use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in real-world heart failure (HF) is...
Abstract Background Recently, two large randomized controlled trials which only included patients wi...
BackgroundSodium-glucose co-transporter 2 inhibitors (SGLT2i) have been associated with favourable o...
Background: Sodium–glucose co-transporter 2 (SGLT2) inhibitors are an emerging class of glucose-lowe...
Abstract Prevention and treatment strategies for heart failure (HF) in diabetes have not been fully ...
BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recent...
BackgroundPatients with type 2 diabetes mellitus (T2DM) and heart failure (HF) are at higher risk of...
Aims: Cardiovascular outcome trials with sodium-glucose co-transporter 2 (SGLT2) inhibitors have dem...
Objective To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2 (SGLT2) ...
Background and Objectives: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) significantly reduce...
Background -Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recent...
Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) were originally developed for the treatment of ...
Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise g...
Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise g...
Aims Use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in real-world heart failure (HF) is ...
AIMS: Use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in real-world heart failure (HF) is...
Abstract Background Recently, two large randomized controlled trials which only included patients wi...
BackgroundSodium-glucose co-transporter 2 inhibitors (SGLT2i) have been associated with favourable o...
Background: Sodium–glucose co-transporter 2 (SGLT2) inhibitors are an emerging class of glucose-lowe...
Abstract Prevention and treatment strategies for heart failure (HF) in diabetes have not been fully ...
BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recent...
BackgroundPatients with type 2 diabetes mellitus (T2DM) and heart failure (HF) are at higher risk of...
Aims: Cardiovascular outcome trials with sodium-glucose co-transporter 2 (SGLT2) inhibitors have dem...
Objective To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2 (SGLT2) ...
Background and Objectives: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) significantly reduce...
Background -Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recent...
Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) were originally developed for the treatment of ...
Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise g...
Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise g...